AusperBio Completes Enrollment in Two Phase II Trials for Hepatitis B Candidate AHB-137

AusperBio Completes Enrollment in Two Phase II Trials for Hepatitis B Candidate AHB-137

By, Admin 23 September 2025

AusperBio Therapeutics has completed patient enrollment in two Phase II clinical trials of its lead drug candidate AHB-137 for chronic hepatitis B (CHB).

Trial Designs

  • AB-10-8007 (NCT07069569): Randomized, open-label, multicenter.
    - Evaluates AHB-137 + HBV vaccine or Peg-IFN in HBeAg-negative patients on nucleos(t)ide analogue (NA) therapy.
  • AB-10-8008 (NCT06829329): Randomized, multicenter.
    - Tests AHB-137 in treatment-naïve CHB patients.

Why Combination Matters

“Combination therapies have been key to curing chronic viral infections like HIV and HCV,”

  • Dr. Guofeng Cheng, CEO, AusperBio.
  • AB-10-8007: Seeks to boost functional cure rates by pairing AHB-137 with existing HBV treatments.
  • AB-10-8008: Expands AHB-137 to a broader HBV patient population.
  • Interim results expected at global conferences in 2026.

Looking Ahead

“Enrollment completion moves us closer to Phase III.”

  • Dr. Chris Yang, CSO, AusperBio.
  • Phase III trial recently approved in China.
  • Company aims to deliver a functional cure for HBV patients globally.

About AHB-137

  • Novel antisense oligonucleotide (ASO).
  • Built using Med-Oligo ASO technology platform.
  • Designed to deliver a dual mechanism of action.
  • Strong data from EASL, AASLD, and APASL presentations.
  • Progressing through multiple Phase II studies and one Phase III trial in China.

AusperBio’s Focus

AusperBio is a clinical-stage biotech with operations in the USA and China.

  • Dedicated to oligonucleotide and targeted delivery technologies.
  • Lead focus: Achieving a functional cure for chronic hepatitis B.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!